Company Filing History:
Years Active: 2019-2020
Title: The Innovations of Anne Leppanen
Introduction
Anne Leppanen is a notable inventor based in Vantaa, Finland. She has made significant contributions to the field of biotechnology, particularly in the development of conjugates involving anti-EGFR1 antibodies. With a total of 2 patents, her work is paving the way for advancements in targeted therapies.
Latest Patents
Leppanen's latest patents focus on conjugates that comprise an anti-EGFR1 antibody or an EGFR binding fragment. The first patent describes a conjugate that includes a dextran derivative with specific substitutions on D-glucopyranosyl units. This innovative approach allows for a bond formation between the dextran derivative and the anti-EGFR1 antibody through a reaction involving aldehyde and amino groups. The second patent mirrors the first, emphasizing the versatility and potential applications of these conjugates in medical treatments.
Career Highlights
Anne Leppanen is currently associated with Tenboron Oy, where she continues to explore and develop her innovative ideas. Her work is characterized by a strong focus on enhancing the efficacy of therapeutic agents through novel conjugation techniques.
Collaborations
Leppanen collaborates with esteemed colleagues such as Filip S Ekholm and Jari Helin, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Anne Leppanen's contributions to biotechnology through her patents and collaborations highlight her role as a leading inventor in her field. Her work continues to inspire advancements in targeted therapies, showcasing the importance of innovation in healthcare.